Schellens JHM - Search Results

1

Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.

Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Mehnert JM, et al. Among authors: schellens jhm. Cancer. 2020 Jul 1;126(13):3021-3030. doi: 10.1002/cncr.32883. Epub 2020 Apr 22. Cancer. 2020. PMID: 32320048 Free article. Clinical Trial.

2

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.

Planting A, Kho S, van der Burg M, Goey H, Schellens J, van den Bent M, van der Gaast A, de Boer-Dennert M, Stoter G, Verweij J. Planting A, et al. Cancer Chemother Pharmacol. 1997;40(4):347-52. doi: 10.1007/s002800050668. Cancer Chemother Pharmacol. 1997. PMID: 9225954 Free article. Clinical Trial.

3

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. Rademaker-Lakhai JM, et al. Clin Cancer Res. 2004 May 15;10(10):3386-95. doi: 10.1158/1078-0432.CCR-03-0315. Clin Cancer Res. 2004. PMID: 15161693 Clinical Trial.

4

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH. Helgason HH, et al. Br J Cancer. 2006 Oct 9;95(7):794-800. doi: 10.1038/sj.bjc.6603332. Epub 2006 Sep 12. Br J Cancer. 2006. PMID: 16969354 Free PMC article. Clinical Trial.

5

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

Siegel-Lakhai WS, Zandvliet AS, Huitema AD, Tibben MM, Milano G, Girre V, Diéras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JH. Siegel-Lakhai WS, et al. Br J Cancer. 2008 Apr 22;98(8):1320-6. doi: 10.1038/sj.bjc.6604300. Epub 2008 Apr 15. Br J Cancer. 2008. PMID: 18414469 Free PMC article.

6

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

Appels NM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JH. Appels NM, et al. Br J Cancer. 2008 Jun 17;98(12):1951-8. doi: 10.1038/sj.bjc.6604402. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506143 Free PMC article. Clinical Trial.

7

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE. Langenberg MH, et al. Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. Clin Cancer Res. 2010. PMID: 20233884 Clinical Trial.

8

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.

Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Jänne PA, et al. Clin Cancer Res. 2011 Mar 1;17(5):1131-9. doi: 10.1158/1078-0432.CCR-10-1220. Epub 2011 Jan 10. Clin Cancer Res. 2011. PMID: 21220471 Free PMC article. Clinical Trial.

9

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Deenen MJ, et al. Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209. Epub 2011 Apr 15. Clin Cancer Res. 2011. PMID: 21498394 Free article.

10

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

Devriese LA, Voest EE, Beijnen JH, Schellens JH. Devriese LA, et al. Cancer Treat Rev. 2011 Dec;37(8):579-89. doi: 10.1016/j.ctrv.2011.04.006. Epub 2011 May 17. Cancer Treat Rev. 2011. PMID: 21592671 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

754 results

Search Page

Filters